Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06292026 · ClinicalTrials.gov registry record · NA
Efficacy of ProgenaMatrix™ in the Management of DFUs
A NA study of Diabetic Foot Ulcer, sponsored by ProgenaCare Global.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06292026: Active NA study of Diabetic Foot Ulcer, sponsored by ProgenaCare Global.
NCT06292026 is a NA study of Diabetic Foot Ulcer that is active but no longer recruiting, run by ProgenaCare Global. The registered enrollment target is 100 participants, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06292026, a NA study of Diabetic Foot Ulcer, is active but no longer recruiting, sponsored by ProgenaCare Global.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™.
Primary Outcome
The endpoint of this data collection process is to study the timepoint for total wound closure following the protocol procedures in the use of ProgenaMatrix™.
Conditions Studied
Interventions
- DEVICE ProgenaMatrix Keratin graft
- OTHER standard of care
Study Locations (1)
Washington
- United Wound Healing - Puyallup
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2026-09 |
| Phase | NA |
What the registry record for NCT06292026 still lists
NCT06292026 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 253-participant average among 67 other Diabetic Foot Ulcer trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 2 interventions - of which ProgenaMatrix Keratin graft is the first listed.
NCT06292026 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT06292026 about?
NCT06292026 is a clinical study titled "Efficacy of ProgenaMatrix™ in the Management of DFUs". This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™.
What is the current status of trial NCT06292026?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-03-14. Estimated completion is 2026-09.
What conditions does trial NCT06292026 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer.
What interventions are being tested in trial NCT06292026?
The interventions under investigation include: ProgenaMatrix Keratin graft (DEVICE), standard of care (OTHER).
Who is sponsoring clinical trial NCT06292026?
This trial is sponsored by ProgenaCare Global, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06292026 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Foot Ulcer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06292026's enrollment target sits among peer trials
100 37th of 67 higher than 28 of 67 other Diabetic Foot Ulcer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Foot Ulcer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers
RECRUITING · NA
-
Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC
RECRUITING · NA
-
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
RECRUITING · NA
-
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
RECRUITING · NA
-
Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
RECRUITING · NA
-
Exercise Enhances Wound Healing in Patients With Diabetic Foot Ulcers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI